Compare
Harvard Bioscience Inc vs Precipio, Inc. vs Bio-Rad Laboratories, Inc. vs Waters Corp
| Latest fiscal year | Harvard Bioscience Inc HBIO | Precipio, Inc. PRPO | Bio-Rad Laboratories, Inc. BIO | Waters Corp WAT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $86.55M | $24.05M | $2.58B | $3.17B |
| Revenue growth (YoY) | -8.1% | +29.8% | +0.7% | +7.0% |
| Gross margin | 57.7% | 44.5% | 51.9% | 59.3% (computed) |
| Operating margin | -56.1% | -5.0% | 1.8% | 25.4% |
| Net margin | -65.5% | -1.5% | 29.4% | 20.3% |
| Net income | -$56.70M | -$363.0K | $759.90M | $642.63M |
| EPS (Diluted) | -$1.28 | -$0.23 | $27.85 | $10.76 |
| Operating cash flow | $6.73M | $685.0K | $532.20M | $652.55M |
| Free cash flow | $5.47M | $359.0K | $374.60M | $539.81M |
| Cash & equivalents | $8.61M | $2.65M | $529.80M | $587.83M |
| Total assets | $80.07M | $21.32M | $10.58B | $5.08B |
| Total liabilities | $66.34M | $6.76M | $3.12B | $2.52B |
| Shareholders' equity | $13.73M | $14.56M | $7.45B | $2.56B |
| Return on year-end equity | -412.8% | -2.5% | 10.2% | 25.1% |
| Shares outstanding | 44.72M | 1.78M | n/a | 59.55M |
Revenue, most recent five fiscal years
| Fiscal year | Harvard Bioscience Inc | Precipio, Inc. | Bio-Rad Laboratories, Inc. | Waters Corp |
|---|---|---|---|---|
| Latest | $86.55M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $2.58B Ended 2025-12-31 | $3.17B Ended 2025-12-31 |
| 1 year earlier | $94.14M Ended 2024-12-31 | $18.53M Ended 2024-12-31 | $2.57B Ended 2024-12-31 | $2.96B Ended 2024-12-31 |
| 2 years earlier | $112.25M Ended 2023-12-31 | $15.20M Ended 2023-12-31 | $2.67B Ended 2023-12-31 | $2.96B Ended 2023-12-31 |
| 3 years earlier | $113.33M Ended 2022-12-31 | $9.41M Ended 2022-12-31 | $2.80B Ended 2022-12-31 | $2.97B Ended 2022-12-31 |
| 4 years earlier | $118.90M Ended 2021-12-31 | $8.85M Ended 2021-12-31 | $2.92B Ended 2021-12-31 | $2.79B Ended 2021-12-31 |